Top

BioDrugs

Published in:

01-10-2009 | Review Article

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor

Current Status and Future Challenges in Cancer Therapy

Authors: Jerry Y. Hsu, Dr Heather A. Wakelee

Published in: BioDrugs | Issue 5/2009

Abstract

The use of monoclonal antibodies targeting the vascular endothelial growth factor (VEGF) pathway has been a significant addition to cancer therapy. One of the VEGF family members, VEGF-A (commonly referred to as VEGF), has been demonstrated to be important in angiogenesis. Although the mechanism of action of these antibodies is still under study, the anti-VEGF antibody bevacizumab has been approved for treatment of various solid cancers including colorectal, lung, and breast cancers as well as glioblastoma and renal cell carcinoma. Addition of bevacizumab to chemotherapy as adjuvant therapy in colorectal cancer did not improve disease-free survival. Bevacizumab is being tested in other clinical settings such as adjuvant therapy, maintenance therapy, and in combination with both chemotherapy and other targeted agents such as the epidermal growth factor receptor kinase inhibitor erlotinib. In addition to bevacizumab, other antibody-based therapies targeting the VEGF pathway are being tested. Ramucirumab and IMC-18F1 are monoclonal antibodies that target the VEGF receptors VEGFR-2 and VEGFR-1, respectively. Aflibercept (VEGF-Trap), a peptide-antibody fusion targeting VEGF ligand, is being tested in clinical trials. Much research is focused on identifying biomarkers to predict which patients will benefit from anti-VEGF therapy. Recent results suggest that VEGF single nucleotide polymorphisms may be predictive of patient response to bevacizumab. Improved imaging modalities such as dynamic contrast-enhanced MRI (DCE-MRI) can better characterize the efficacy of anti-angiogenic agents. As anti-VEGF treatments such as bevacizumab have been integrated into the treatment of many different types of cancers, the development of bevacizumab-resistant tumors has become more common. Recent studies show that targeting other angiogenesis signaling pathways such as platelet-derived growth factor-C (PDGF-C), Bombina variagata peptide 8 (Bv8, also known as prokineticin-2), and VEGFR-3 may lead to enhanced response in anti-VEGF resistant tumors. In the future, tailored treatments consisting of combinations of chemotherapy, other targeted therapies, and anti-angiogenesis agents will hopefully result in better patient outcomes.

Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002 Oct; 2(10): 795–803PubMedCrossRef

Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005 Feb 10; 23(5): 1011–27PubMedCrossRef

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003 Jun; 9(6): 669–76PubMedCrossRef

Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008 Aug; 8(8): 579–91PubMedCrossRef

Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000 Sep 14; 407(6801): 249–57PubMedCrossRef

Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun 3; 350(23): 2335–42PubMedCrossRef

Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008 Apr 20; 26(12): 2013–9PubMedCrossRef

Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 Apr 20; 25(12): 1539–44PubMedCrossRef

Wolmark N, Yothers G, O'Connell M, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08 [abstract LBA4]. J Clin Oncol 2009; 27 (18 Suppl.): 793s

10.

Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 Dec 14; 355(24): 2542–50PubMedCrossRef

11.

Reck M, Von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009 Feb 2; 27(8): 1227–34PubMedCrossRef

12.

Jones D. Avastin-Tarceva combination fails in lung cancer. Nat Biotechnol 2009 Feb; 27(2): 108–9PubMedCrossRef

13.

Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract LBA8002]. American Society of Clinical Oncology (ASCO) Annual Meeting 2009; 2009 May 29–Jun 2; Orlando (FL)

14.

Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 Dec 27; 357(26): 2666–76PubMedCrossRef

15.

Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract LBA1011]. American Society of Clinical Oncology (ASCO) Annual Meeting 2008; 2008 May 30–Jun 3; Chicago (IL)

16.

Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [abstract 1005]. J Clin Oncol 2009; 27 (15 Suppl.): 42sCrossRef

17.

Clinicaltrials.gov. A study to evaluate the safety and efficacy of bevacizumab in combination with chemotherapy in previously treated metastatic breast cancer (RIBBON 2) [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00281697?term=NCT00281697&rank=1 [Accessed 2009 Aug 12]

18.

Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 Feb 1; 23(4): 792–9PubMedCrossRef

19.

Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007 Dec 22; 370(9605): 2103–11PubMedCrossRef

20.

Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008 Nov 20; 26(33): 5422–8PubMedCrossRef

21.

Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) [abstract 4508]. J Clin Oncol 2007; 25 (18 Suppl.): 4508

22.

Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 Jan 1; 21(1): 60–5PubMedCrossRef

23.

Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009 Feb 5; 360(6): 563–72PubMedCrossRef

24.

Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009 Feb; 20(2): 227–30PubMedCrossRef

25.

Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009 Feb 10; 27(5): 672–80PubMedCrossRef

26.

Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007 Oct 10; 25(29): 4557–61PubMedCrossRef

27.

Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009 May 4; 27(20): 3385–90PubMedCrossRef

28.

Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 Jun 1; 22(11): 2184–91PubMedCrossRef

29.

Hainsworth J, Herbst RS. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab in combination with erlotinib compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line therapy (BeTa) [abstract]. J Thorac Oncol 2008; 3(11): S302

30.

Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008 Jan 1; 26(1): 60–5PubMedCrossRef

31.

Wakelee HA, Dahlberg SE, Brahmer JR, et al. Increased benefit from bevacizumab (BEV) in younger women with advanced NSCLC on Eastern Cooperative Oncology Group (ECOG) 4599 [abstract]. J Thorac Oncol 2008; 3(11): S282

32.

Lynch T, Brahmer J, Fischbach N, et al. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS) [abstract 8077]. American Society of Clinical Oncology (ASCO) Annual Meeting 2008; 2008 May 30–Jun 3; Chicago (IL)

33.

Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2008 Dec 29; 27(5): 740–5PubMedCrossRef

34.

A study to evaluate bevacizumab alone or in combination with irinotecan for treatment of glioblastoma multiforme (BRAIN) [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00345163 [Accessed 2009 Aug 12]

35.

US FDA. Bevacizumab injection [online]. Available from URL: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm149364.htm [Accessed 2009 Aug 12]

36.

Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009 May 20; 27(15): 2542–52PubMedCrossRef

37.

Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 Jul 31; 349(5): 427–34PubMedCrossRef

38.

Escudier B, Bellmunt J, Negrier S, et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) +interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) [abstract 5020]. J Clin Oncol 2009; 27 (15 Suppl.): 239sCrossRef

39.

Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206 [abstract LBA5019]. J Clin Oncol 2009; 27 (18 Suppl.): 798s

40.

National Cancer Institute. FDA approval for bevacizumab [online]. Available from URL: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab [Accessed 2009 Aug 31]

41.

Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM) [abstract 7526]. J Clin Oncol 2007; 25 (18 Suppl.): 7526

42.

Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008 Aug 15; 113(4): 808–14PubMedCrossRef

43.

Griesinger F, Laskin JJ, Pavlakis N. Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO19390 (SAiL) [abstract 8049]. American Society of Clinical Oncology (ASCO) Annual Meeting 2008; 2008 May 30–Jun 3; Chicago (IL)

44.

Akerley WL, Langer C, Oh Y, et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer [abstract 8043]. American Society of Clinical Oncology (ASCO) Annual Meeting 2008; 2008 May 30–Jun 3; Chicago (IL)

45.

Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009 Mar 20; 27(9): 1405–12PubMedCrossRef

46.

Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20Suppl. 4: 61–3PubMed

47.

Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009 Jan 12; 27(6): 843–50PubMedCrossRef

48.

Sessa C, Guibal A, Del Conte G, et al. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008 Jul; 5(7): 378–91PubMedCrossRef

49.

Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009 Jun; 10(6): 597–605PubMed

50.

Spratlin JL, Gore L, Camidge DR, et al. A phase I, pharmacological and biological study of weekly IMC-1121B, a recombinant human IgG 1 monoclonal antibody (MAb), targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients (pts) with advanced solid tumors [abstract A33]. AACR-NCI-EORTC International Conference; 2007 Oct 22; San Francisco (CA)

51.

Wu Y, Zhong Z, Huber J, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006 Nov 1; 12(21): 6573–84PubMedCrossRef

52.

Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008 Oct 1; 26(28): 4672–8PubMedCrossRef

53.

Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008 Aug 1; 26(22): 3709–14PubMedCrossRef

54.

Cannistra SA. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol 2008 Aug 1; 26(22): 3665–7PubMedCrossRef

55.

Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008 Jan 20; 26(3): 374–9PubMedCrossRef

56.

Tappenden P, Jones R, Paisley S, et al. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007 Nov; 43(17): 2487–94PubMedCrossRef

57.

Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008 Jun 20; 26(18): 2992–8PubMedCrossRef

58.

Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005 Jun 20; 23(18): 4162–71PubMedCrossRef

59.

Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007 Oct 20; 25(30): 4714–21PubMedCrossRef

60.

Longo R, Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 2007 Jul; 60(2): 151–70PubMedCrossRef

61.

Longo R, Gasparini G. Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev Mol Diagn 2008 May; 8(3): 301–14PubMedCrossRef

62.

Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006 Jan 10; 24(2): 217–27PubMedCrossRef

63.

Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005 Jul 6; 97(13): 981–9PubMedCrossRef

64.

Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008 Mar 1; 14(5): 1407–12PubMedCrossRef

65.

Zhang W, Dahlberg SE, Yang D, et al. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599 [abstract 8032]. J Clin Oncol 2009; 27 (15 Suppl.): 414sCrossRef

66.

Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27(18): 3020–6PubMedCrossRef

67.

Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005 Nov 1; 23(31): 8136–9PubMedCrossRef

68.

Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008 Aug; 8(8): 592–603PubMedCrossRef

69.

Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009 Mar 3; 15(3): 220–31PubMedCrossRef

70.

Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009 Mar 3; 15(3): 232–9PubMedCrossRef

71.

Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009 Jan 6; 15(1): 21–34PubMedCrossRef

72.

Shojaei F, Wu X, Zhong C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007 Dec 6; 450(7171): 825–31PubMedCrossRef

73.

Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008 Jul 31; 454(7204): 656–60PubMedCrossRef

74.

Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27(18): 3027–35PubMedCrossRef

Title: Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor
Current Status and Future Challenges in Cancer Therapy
Authors: Jerry Y. Hsu
Dr Heather A. Wakelee
Publication date: 01-10-2009
Publisher: Springer International Publishing
Published in: BioDrugs / Issue 5/2009
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.2165/11317600-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor

Current Status and Future Challenges in Cancer Therapy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

RNA Interference Technologies and Therapeutics

Recombinant Human Thrombin

Progress towards Therapeutic Application of RNA Interference for HIV Infection

Therapeutic Breast Cancer Vaccines